ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics.

[ImmuPharma PLC @ImmuPharma]

#ImmuPharma Initiates IND-Enabling Program for #Kapiglucagon to treat Diabetes - https://t.co/SRu24YCJMO

[ImmuPharma PLC @ImmuPharma]

#ImmuPharma's Open Letter to Shareholders from Chairman, following Tuesday's General Meeeting, where both resolutions approved, paving the way for investment in #Kapiglugcaon, whilst the continued focus on completing a partnering deal in 2026 for #P140 - https://t.co/d5oIYe1dHV

[ImmuPharma PLC @ImmuPharma]

#IMM issues new update on #P140 program including:
- patent progress |new supporting data | scientific publication in preparation -https://t.co/BflIwoAejf

[ImmuPharma PLC @ImmuPharma]

#ImmuPharma's management team provided a presentation via the #Investor Meet Company platform this afternoon, talking through partnering discussions on P140, fundraising and investment in its #type 1 Diabetes program, #Kapiglucagon - https://t.co/hFAhUaiYxQ

[ImmuPharma PLC @ImmuPharma]

#ImmuPharma's management team will be presenting on the Investor Meet Company #IMC platform on Friday 20 March 2026 @ 12 midday (GMT) - https://t.co/BV42G4sFfn

[ImmuPharma PLC @ImmuPharma]

Tim McCarthy, CEO of #ImmuPharma talks to Proactive Investor about #P140 deal discussions still on track for 2026, new diabetes asset, #Kapiglucagon and up to £7.5m fundraising - https://t.co/IVNVNw0cFj

[ImmuPharma PLC @ImmuPharma]

#ImmuPharma's CEO, Tim McCarthy talks to Proactive Investor on positive partnering discussions for its #auto-immune platform #P140 and its robus cash runway until Q4 2026
Link: https://t.co/xUdJXOxo8B

[ImmuPharma PLC @ImmuPharma]

Please see below a link to an interview from Tim McCarthy, CEO of #ImmuPharma, providing further context on positive parterning discussions on the P140 platform, following #ImmuPharma's corporate update announced on Monday.
https://t.co/MUCRWitH5o

[ImmuPharma PLC @ImmuPharma]

#ImmuPharma confirms today in a Corporate Update that partnering discussions going well and "#ImmuPharma’s objective is to identify “the best fit” partner for its # P140 #auto-immune platform technology, with a deal now moving into 2026.https://t.co/r3aBv8RbnW

[ImmuPharma PLC @ImmuPharma]

#IMM attending #BIO-EUROPE VIENNA - 3/5 NOV

https://t.co/E9oks8yhVc

[ImmuPharma PLC @ImmuPharma]

#ImmuPharma announces the launch of its new website and Corporate Update - #www.immupharma.co.uk

[ImmuPharma PLC @ImmuPharma]

Immupharma., by @that_stocks_guy https://t.co/HOjiAAOZ6h

[ImmuPharma PLC @ImmuPharma]

#IMM announces appointment of Ketan Patel to the Board.
Ketan Patel, commented:
"After nearly three decades of investing in mid and small cap UK companies with a focus on healthcare and life science, I am delighted to be joining the ImmuPharma team at this pivotal stage."

[ImmuPharma PLC @ImmuPharma]

"Putting Patients into Remission": #ImmuPharma's Autoimmune Breakthrough #P140
Tim McCarthy, CEO of #ImmuPharma, talks to Stockhouse 'WatchList', in another strategic interview following the Company's game changing announcement on 1st September 2025

https://t.co/GXeoXH5EfN

[ImmuPharma PLC @ImmuPharma]

#ImmuPharma's CEO, Tim McCarthy talks to Zak Mir at #Traders Cafe on the filing of the new groundbreaking #P140 patent for autoimmune diseases and how 2025 will be a transformation year

Link:https://t.co/znjo1V7HSC

[ImmuPharma PLC @ImmuPharma]

Midweek Takeaway featuring #ImmuPharma's Tim McCarthy, CEO, and Dr Sébastien Goudreau, CSO talking about the recently announced groundbreaking filing of a new patent for its lead asset P140.

Link: https://t.co/5UdOEzPjvU

[ImmuPharma PLC @ImmuPharma]

#'IMMs (AIM:IMM) CEO, Tim McCarthy and CSO, Dr Sébastien Goudreau, talked with Proactive about the Company's latest milestone — the filing of a new patent application for its lead drug candidate #P140, described as the world's first "immunormaliser"… https://t.co/rpwL1CruRT

[ImmuPharma PLC @ImmuPharma]

ImmuPharma Files Groundbreaking New Patent Application for P140: First-in-Class ‘Immunormalizer’ for Precision Diagnosis and Treatment of Autoimmune Diseases

https://t.co/O7Ozj2P6qz

[ImmuPharma PLC @ImmuPharma]

Tim McCarthy, CEO of #IMM talks to Zak Mir, 'Traders Cafe' on the UK biotech arena as a public company with 2 key scientific announcements issued by #IMM over the last period & details on the #MOA of #IMMs P140 auto-immune technology platform
https://t.co/awjkGTBGQi

[ImmuPharma PLC @ImmuPharma]

Tim McCarthy, CEO of #ImmuPharma, talks to #Sunday Roast team, on two key scientific milestones, the most recent announced on 13 March, on the MOA of P140 - and its commercial value - https://t.co/ImnuBzki6c via @YouTube